je.st
news
NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
2015-02-23 13:00:00| Merck.com - Corporate News
Dateline City: SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J. Partnership Combines NGMs Unique Biology-focused Research Platform with Mercks Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)-- NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestor Relations:Justin Holko, 908-740-1879orNGM BiopharmaceuticalsMedia Relations:Tony Plohoros, 908-940-01356 Degreestplohoros@6degreespr.comorInvestor Relations:Beth DelGiacco, 212-362-1200Stern Investor Relationsbeth@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: develop
broad
discover
collaboration
Category:Biotechnology and Pharmaceuticals